<DOC>
	<DOCNO>NCT01703949</DOCNO>
	<brief_summary>This pilot clinical trial study brentuximab vedotin treating patient CD30+ lymphoma come base period improvement respond treatment . Biological therapy , brentuximab vedotin , may stimulate immune system different way stop cancer cell grow .</brief_summary>
	<brief_title>Brentuximab Vedotin Treating Patients With Relapsed Refractory CD30+ Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate response rate follow weekly brentuximab vedotin ( 1.2 mg/kg 3 4 week four 28-day cycle ) patient lack response ( &lt; partial response [ PR ] ) progression follow brentuximab vedotin demonstrate persistent expression CD30 . SECONDARY OBJECTIVES : I . To monitor clinical outcome follow study treatment regimen . II . To estimate frequency CD30 loss patient follow resistance brentuximab vedotin . III . To describe pattern CD30 expression ( membranous , cytoplasmic , Golgi ) comparison pre-brentuximab vedotin expression . IV . To semi-quantitatively estimate compare surface density CD30 pre post brentuximab vedotin measure flow cytometry . V. To correlate response CD30 density measure flow cytometry . VI . To evaluate tolerability weekly regimen patient previously expose brentuximab vedotin . OUTLINE : Patients receive brentuximab vedotin intravenously ( IV ) 30 minute day 1 , 8 , 15 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3-5 week , every 3 month 1 year , every 6 month 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Relapsed refractory CD30+ lymphoma either achieve &lt; PR brentuximab vedotin ( minimum 2 cycle ) progress receive brentuximab vedotin Documented expression CD30 tumor cell follow last dose brentuximab vedotin Absolute neutrophil count ( ANC ) &gt; 1,000/uL Platelets &gt; 50,000/uL Serum creatinine &lt; 1.5 mg/dL OR creatinine clearance &gt; 60 mL/min Bilirubin &lt; 1.5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5 x ULN Measurable disease compute tomography ( CT ) similar ( e.g . magnetic resonance image [ MRI ] ) criterion ( &gt; 1.5 cm ) Resolution nonhematologic brentuximab vedotinrelated adverse event ( AEs ) &lt; grade 2 All patient must inform investigational nature study give write consent accordance institutional federal guideline Patients must anticipate complete least 2 cycle chemotherapy study Expected survival untreated &gt; 90 day Prior transplant within 100 day Radioimmunotherapy within 12 week Known human immunodeficiency virus ( HIV ) hepatitis B positivity Active infection medical condition would preclude treatment opinion principal investigator Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 Known active central nervous system ( CNS ) involvement Peripheral neuropathy &gt; grade 1 due brentuximab vedotin peripheral neuropathy &gt; grade 2 Intolerance brentuximab vedotin Concurrent use anticancer agent experimental treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>